ArticleClinical and experimental immunology2004
Dysregulation of IL-2 and IL-8 production in circulating T lymphocytes from young cystic fibrosis patients.
Article in Clinical and experimental immunology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- A pilot trial on safety and efficacy of erythrocyte-mediated steroid treatment in CF patients.BMC pediatrics · 2006Trial
- Pediatric cystic fibrosis is associated with type 3 immune response.Molecular biology reports · 2026Article
- Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions.Frontiers in genetics · 2021Review
- Suppression of the TGF-β pathway by a macrolide antibiotic decreases fibrotic responses by ocular fibroblastsRoyal Society open science · 2020Article
- Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis.BMC medical research methodology · 2019Observational
- A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis.Nature communications · 2017Article
- Azithromycin use in patients with cystic fibrosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015Review
- Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis.PloS one · 2012Article
- Abnormal trafficking and degradation of TLR4 underlie the elevated inflammatory response in cystic fibrosis.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells.Clinical and experimental immunology · 2007Article
- New insights into pulmonary inflammation in cystic fibrosis.Archives of disease in childhood · 2006Review
- Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes.Respiratory research · 2006Article
- Lymphocytes in cystic fibrosis lung disease: a tale of two immunities.Clinical and experimental immunology · 2004Article
- Platelet factor 4 is highly upregulated in dendritic cells after severe trauma.Molecular medicine (Cambridge, Mass.)Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well documented that patients with cystic fibrosis (CF) are unable to clear persistent airway infections in spite of strong local inflammation, suggesting a dysregulation of immunity in CF. We and others have reported previously that T lymphocytes may play a prominent role in this immune imbalance. In the present work, we compared the reactivity of CD3+ T cells obtained from young CF patients in stable clinical conditions (n = 10, aged 9-16.5 years) to age-matched healthy subjects (n = 6, aged 9-13.5 years). Intracellular levels of interferon (IFN)-gamma, interleukin (IL)-2, IL-8 and IL-10 were determined by flow cytometry after whole blood culture. The data identified T lymphocyte subsets producing either low levels (M1) or high levels (M2) of cytokine under steady-state conditions. We found that the production of IFN-gamma and IL-10 by T lymphocytes was similar between young CF patients and healthy subjects. In contrast, after 4 h of activation with PMA and ionomycin, the percentage of T cells producing high levels of IL-2 (M2) was greater in CF patients (P = 0.02). Moreover, T cells from CF patients produced lower levels of IL-8, before and after activation (P = 0.007). We conclude that a systemic immune imbalance is present in young CF patients, even when clinically stable. This disorder is characterized by the capability of circulating T lymphocytes to produce low levels of IL-8 and by the emergence of more numerous T cells producing high levels of IL-2. This imbalance may contribute to immune dysregulation in CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.